Empower Pharmacy
Houston compounder operating a 503A pharmacy (7601 N. Sam Houston Pkwy W.) and a 503B outsourcing facility (5980 W. Sam Houston Pkwy N.). Named as a partner pharmacy by Emerge and Willow. Eli Lilly sued it over compounded tirzepatide in 2025, and FDA's September 2026 warning letter cites large-volume compounding of semaglutide and tirzepatide copies.
Legal name: Empower Clinic Services, LLC (dba Empower Pharmacy / Empower Pharma)
Makes or dispenses: semaglutide, tirzepatide, testosterone cypionate, testosterone cream, testosterone troches, enclomiphene
Telehealth brands that use Empower Pharmacy
Same pharmacy, different provider: these brands fill prescriptions through the same pharmacy but differ in price, clinical support, and billing. Their cheapest ongoing GLP-1 prices run from $224 to $299/mo.
FDA and regulatory record
Warning letters and Form 483s record problems FDA found during an inspection at the time. They don't by themselves mean the medication you receive today is unsafe, and pharmacies often fix the issues. Check the dates, and read the source documents.
- Sep 18, 2026 · FDA warning letter
503A pharmacy: compounded large volumes of semaglutide and tirzepatide that FDA calls essentially copies of approved drugs, plus sterility/CGMP failures; follows Form 483 issued 2025-11-14.
Source → - Apr 2, 2025 · FDA warning letter
503B facility (5980 W. Sam Houston Pkwy N.): sterile drugs produced under insanitary conditions and CGMP failures; follows Form 483 issued 2024-08-28.
Source → - Apr 2, 2025 · FDA warning letter
503A pharmacy (7601 N. Sam Houston Pkwy W.): sterile products prepared under insanitary conditions (environmental monitoring, media fills, stopper sterilization); follows Form 483 issued 2024-10-04.
Source → - 2025 · Lawsuit
Eli Lilly filed suit against Empower (and Strive Pharmacy) over compounded tirzepatide.
Source → - Dec 1, 2023 · Form 483
FDA issued a Form 483 to Empower Clinic Services dba Empower Pharmacy in Houston.
Source → - Oct 15, 2021 · FDA warning letter
Sent to Empower's 503B outsourcing facility at 5980 W Sam Houston Pkwy N. FDA said drugs produced there did not meet the section 503B conditions.
Source → - May 25, 2017 · FDA warning letter
Followed a Nov 2015 inspection at 12123 Jones Rd, Houston. FDA found some drugs were made without valid patient-specific prescriptions and cited serious deficiencies in sterile drug production.
Source →
Questions about Empower Pharmacy
Which telehealth companies use Empower Pharmacy?
▾
Among the brands we track: Defy Medical, Emerge Weight Loss, Willow. Each of these brands names the pharmacy in its own materials.
What kind of pharmacy is Empower Pharmacy?
▾
Empower Pharmacy is listed as: 503a compounding pharmacy · 503b outsourcing facility, based in Houston, TX. 503A pharmacies compound medication for individual patient prescriptions under state board oversight; 503B outsourcing facilities register with the FDA and follow federal manufacturing standards (CGMP).
Has Empower Pharmacy received FDA warning letters?
▾
We found 7 regulatory records, the most recent dated Sep 18, 2026. Each is listed on this page with a link to the source document.
Sources
- https://www.emergeweight.com/faq
- https://www.startwillow.com/terms-and-conditions
- https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/empower-clinic-services-llc-dba-empower-pharmacy-738238-09182026
- https://www.defymedicalstore.com/pharmacy-contact-info
- https://www.defymedicalstore.com/medications/testosterone?pharmacy=Empower
- https://npiregistry.cms.hhs.gov/api/?version=2.1&number=1730449299
Researched 2026-09-26.